Sepsivac – A First-In-The-World Innovation for Sepsis Management

To revolutionize Sepsis management, Cadila Pharmaceuticals introduces Sepsivac, an immunotherapy treatment. It’s the first-in-the-world innovation in Sepsis management and the drug has received approval from Drug Controller General of India (DCGI) for immunotherapy treatment in Sepsis or septic shock. Sepsivac contains mycobacterium w, an immunomodulator which is a non-pathogenic mycobacterium. As a result of the immunomodulator effect, Sepsivac effectively saves more lives in sepsis. Randomized trials in sepsis patients showed 11% absolute reduction and 55.5% relative reduction in mortality. Sepsivac reduces the days on ventilator, ICU stay, hospital stay, incidences of secondary infection and days on vasopressor & reduces the SOFA score.